Clinical trials: Ebola Virus Disease
Ebola Virus Disease
Efficacy of Favipiravir Against Severe Ebola Virus Disease
The purpose of this study is to explore the therapeutic efficacy of Favipiravir, a broad-spectrum antiviral drug against severe cases of Ebola Virus Disease (EVD), which is the most difficult aspect for clinical management of EVD…
- Trial name
- NCT02662855
- Testing
- WHO-recommended therapies, Favipiravir
- Volunteers
- 77 people
- Sponsor
- Beijing Institute of Pharmacology and Toxicology
Ebola Viruses
Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)
Ebola virus has infected and killed people, mostly in Africa. In 2014, the Zaire ebolavirus (ZEBOV) has affected several thousand people. There is no approved effective way to treat or prevent Ebola.
- Trial name
- NCT02280408
- Testing
- V920
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ebola Virus Disease
ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)
An open-label, single arm phase II study of the candidate Ebola Vaccine Ad26.ZEBOV/MVA-BN®-Filo
- Trial name
- NCT04028349
- Testing
- Ad26.ZEBOV/MVA-BN-Filo
- Where
- Uganda
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
Ebola Virus Disease
Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)
The purpose of this study is to evaluate the efficacy and safety of amiodarone in the treatment of patients afflicted with Ebola virus disease.
- Trial name
- EASE (NCT02307591)
- Testing
- Best Supportive Care, Best Supportive Care + Amiodarone
- Sponsor
- Emergency NGO Onlus
Cataract
PREVAIL VII: Cataract Surgery in Ebola Survivors
Objective: Zaire ebolavirus is a single-stranded RNA virus associated with high morbidity and mortality. The most recent epidemic of Ebola virus disease (EVD) in West Africa resulted in over 11,000 deaths and disabling sequelae…
- Trial name
- NCT03309020
- Testing
- Cataract surgery
- Where
- Liberia
- Volunteers
- 37 people
- Sponsor
- National Eye Institute (NEI)
Healthy
A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV administered as heterologous prime-boost vaccine regimens in healthy adult participants.
- Trial name
- NCT02376426
- Testing
- MVA-BN-Filo, Ad26.ZEBOV
- Where
- Kenya
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants
The main objective of this trial is to evaluate the safety and reactogenicity of mRNA-1469
- Trial name
- NCT07737717
- Testing
- mRNA-1469
- Where
- 3 sites in Canada
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Ebola
GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Background: Some people have Ebola virus in their body for months after they recover from Ebola virus disease. Some may have health problems from the virus while others are fine.
- Trial name
- NCT02818582
- Testing
- GS-5734
- Where
- 2 sites in Guinea, Liberia
- Volunteers
- 38 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hemorrhagic Fever, Ebola
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
The purpose of this study is to assess the safety, tolerability and immunogenicity of different vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens in healthy and…
- Trial name
- NCT02598388
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in United States, Kenya and 4 more
- Volunteers
- 578 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Healthy
A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women
The purpose of this study is: a) to assess adverse maternal/fetal outcomes in pregnant women randomized to receive the 2- dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo [Group A]) and in control women (unvaccinated pregnant…
- Trial name
- INGABO (NCT04556526)
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 3 sites in Rwanda
- Volunteers
- 4,031 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola Virus Disease, Marburg Virus Disease
Evaluating an Ebola and a Marburg Vaccine in Uganda
This study will test two new vaccines, one for Ebola and one for Marburg virus, to see if they are safe, if they have side effects, and if they create an immune response in people who receive them.
- Trial name
- NCT00997607
- Testing
- Ebola vaccine, Marburg vaccine
- Where
- Uganda
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV as heterologous prime-boost vaccine regimens in healthy adult participants.
- Trial name
- NCT02313077
- Testing
- MVA-BN-filo, Ad26. ZEBOV
- Where
- United Kingdom
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Hemorrhagic Fever, Ebola
Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults
The purpose of this study is to evaluate the safety, infectivity, and immunogenicity of the HPIV3-EbovZ GP Ebola vaccine candidate in healthy adults.
- Trial name
- NCT02564575
- Testing
- HPIV3-EbovZ GP Vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
The purpose of this study is to demonstrate the non-inferiority of a heterologous prime-boost regimen using Ad26.ZEBOV as prime and MVA-BN-Filo as boost administered at different doses at a 56-day interval versus the same regimen…
- Trial name
- NCT02543567
- Testing
- Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp)
- Where
- 6 sites in United States
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola Virus Disease
Prophylaxis Vaccine Antibodies Ebola
Three measures are currently being implemented to control Ebola outbreaks: Monitoring of contacts Isolation and treatment of sick people Vaccination of the population in high-risk areas.
- Trial name
- PROVAE (NCT04822376)
- Testing
- ansuvimab, Ervebo
- Where
- Guinea
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Ebola Virus Disease
Multiple Treatments for Ebola Virus Disease (EVD)
The purpose of this study is to determine whether multiple therapeutic regimens are effective in the treatment of Ebola Virus Disease (EVD)
- Trial name
- NCT02380625
- Testing
- Azithromycin, Sunitinib and Erlotinib, Atorvastatin and Irbesartan
- Volunteers
- 150 people
- Sponsor
- Clinical Research Management, Inc.
Ebola Virus Disease
An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus Disease
Open-label safety, tolerability, pharmacokinetics and immunogenicity study in three dose escalation groups
- Trial name
- NCT04717830
- Testing
- Gamezumab
- Where
- Russia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Hemorrhagic Fever, Ebola
STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)
The 2014 outbreak of Ebola in West Africa is the largest in recorded history with widespread and intense transmission in Guinea, Liberia, and Sierra Leone.
- Trial name
- STRIVE (NCT02378753)
- Testing
- rVSVΔG-ZEBOV
- Where
- 5 sites in Sierra Leone
- Volunteers
- 8,651 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Healthy
Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers
Background: Ebola is a virus that can spread quickly and causes serious disease. It is currently causing an outbreak in West Africa. There are no approved treatments for Ebola.
- Trial name
- NCT02389192
- Testing
- ZMAPP
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Ebola Virus Disease
A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
The objective of this Phase 1 safety study is to provide access to the potential therapeutic benefit of EBOV convalescent plasma containing antibodies to EBOV.
- Trial name
- NCT02295501
- Testing
- INTERCEPT Plasma
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Cerus Corporation